Co-delivery of Cu(I) chelator and chemotherapeutics as a new strategy for tumor theranostic
- 12 February 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Controlled Release
- Vol. 321, 483-496
- https://doi.org/10.1016/j.jconrel.2020.02.023
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81872808)
- Program of Shanghai Academic Research Leader (18XD1400500)
- Shanghai Municipal Science and Technology Major Project (2018SHZDZX01)
- ZJLab, Fudan-SIMM Joint Research Fund (FU-SIMM20182006)
- Scientific Research Program of Shanghai Health and Family Planning Commission (20184Y0149)
This publication has 42 references indexed in Scilit:
- Targeting cellular metabolism to improve cancer therapeuticsCell Death & Disease, 2013
- A Targetable Fluorescent Sensor Reveals That Copper-Deficient SCO1 and SCO2 Patient Cells Prioritize Mitochondrial Copper HomeostasisJournal of the American Chemical Society, 2011
- Development of photostable near-infrared cyanine dyesChemical Communications, 2010
- Tetrathiomolybdate Inhibits Copper Trafficking Proteins Through Metal Cluster FormationScience, 2010
- Structural Biology of Copper TraffickingChemical Reviews, 2009
- Technology of Hyperthermic Intraperitoneal Chemotherapy in the United States, Europe, China, Japan, and KoreaThe Cancer Journal, 2009
- Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bioluminescenceJournal of Controlled Release, 2009
- Elevated copper and oxidative stress in cancer cells as a target for cancer treatmentCancer Treatment Reviews, 2009
- Zinc and tetrathiomolybdate for the treatment of Wilson’s disease and the potential efficacy of anticopper therapy in a wide variety of diseasesMetallomics, 2009
- Copper-Dioxygen Complexes. Inorganic and Bioinorganic PerspectivesChemical Reviews, 1994